Stopping immunosuppression after failed kidney transplant
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares what happens when patients with a failed kidney transplant (still in the body) stop their immunosuppressant medicines at 6 months versus continuing them. The goal is to safely prevent your immune system from becoming too sensitive, which can make finding a new donor kidney harder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had at least one kidney transplant that failed and is still in your body for at least 3 months.
- You are currently on dialysis (hemodialysis or peritoneal dialysis) for less than 6 months.
- You are taking the immunosuppressant medicines tacrolimus or cyclosporine along with steroids.
- Your cPRA blood test result is 90% or less.
- You are not pregnant and, if able to have children, agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes older kidney transplant patients (65+) who take a specific anti-rejection drug called tacrolimus once a day. It looks at their long-term outcomes to help improve care for people in this age group.
This study tests whether continuing certain anti-rejection medicines while on dialysis can help lower the risk of your immune system becoming too sensitive to a future kidney transplant. It might help you stay eligible for another transplant later.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Hear when a new Chronic Renal Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.